<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Interferon regulatory factor-4 (IRF-4) is a hematopoietic cell-restricted transcription factor important for hematopoietic development and immune response regulation </plain></SENT>
<SENT sid="1" pm="."><plain>It was also originally identified as the product of a proto-oncogene involved in chromosomal translocations in <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast to its oncogenic function in late stages of B lymphopoiesis, expression of IRF-4 is down-regulated in certain myeloid and early B-lymphoid <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In this study, we found that the IRF-4 protein levels are increased in lymphoblastic cells transformed by the BCR/ABL oncogene in response to BCR/ABL <z:chebi fb="0" ids="38637">tyrosine kinase inhibitor</z:chebi> <z:chebi fb="0" ids="45783">imatinib</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>We further found that IRF-4 deficiency enhances BCR/ABL transformation of B-lymphoid progenitors in vitro and accelerates disease progression of BCR/ABL-induced <z:hpo ids='HP_0011009'>acute</z:hpo> B-lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) in mice, whereas forced expression of IRF-4 potently suppresses BCR/ABL transformation of B-lymphoid progenitors in vitro and BCR/ABL-induced <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>Further analysis showed that IRF-4 inhibits growth of BCR/ABL+ B lymphoblasts primarily through negative regulation of cell-cycle progression </plain></SENT>
<SENT sid="6" pm="."><plain>These results demonstrate that IRF-4 functions as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor in early B-cell development and may allow elucidation of new molecular pathways significant to the lymphoid <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> by BCR/ABL </plain></SENT>
<SENT sid="7" pm="."><plain>The context dependent roles of IRF-4 in <z:e sem="disease" ids="C1326912" disease_type="Neoplastic Process" abbrv="">oncogenesis</z:e> should be an important consideration in developing <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapies targeting IRF-4 </plain></SENT>
</text></document>